mp.weixin.qq.com·· 14 hours agoScore68
AstraZeneca Launches Sunvozertinib (ZEGFROVY) in the United States
In brief
On October 23, 2026, Dizhe (Dizal) announced that its global strategic partner AstraZeneca has officially launched sunvozertinib (ZEGFROVY) in the United States. The drug treats adults with locally advanced or metastatic NSCLC with confirmed EGFR exon20ins whose disease progressed on or who are intolerant to platinum-based chemotherapy. Its first-line indication application has been accepted by both CDE and FDA.
Source: mp.weixin.qq.com · mp.weixin.qq.com